2021
Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer
Slovak RJ, Park HJ, Kamp WM, Ludwig JM, Kang I, Kim HS. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Scientific Reports 2021, 11: 6956. PMID: 33772035, PMCID: PMC7997991, DOI: 10.1038/s41598-021-85810-5.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDCD4-Positive T-LymphocytesCell Line, TumorCell ProliferationColorectal NeoplasmsCTLA-4 AntigenFemaleHepatitis A Virus Cellular Receptor 2Immune Checkpoint InhibitorsLymphocyte Activation Gene 3 ProteinLymphocytes, Tumor-InfiltratingMaleMiceMice, Inbred BALB CMicrosatellite RepeatsProgrammed Cell Death 1 ReceptorSpleenT-Lymphocytes, CytotoxicConceptsDual checkpoint inhibitionPD-1 inhibitionColorectal cancerCheckpoint inhibitionPD-1Checkpoint inhibitorsT cellsImmune responseRobust anti-tumor immune responseAnti-PD-1 groupAnti-PD-1 antibodyAnti-tumor immune responseMicrosatellite stable colorectal cancerDual PD-1Majority of patientsDeficient mismatch repairStable colorectal cancerCTLA-4 inhibitionTumor growth rateHigh microsatellite instabilityPotential escape mechanismsCombination immunotherapyImmunosuppressive checkpointsTumoral infiltrationDual therapy
2020
Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Kamp W, Park H, Slovak R, Ludwig J, Kang I, Kim H. Quantification of immune response after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Journal Of Clinical Oncology 2020, 38: 160-160. DOI: 10.1200/jco.2020.38.4_suppl.160.Peer-Reviewed Original ResearchDual immune checkpoint blockadeAnti-PD-1 antibodyColorectal cancerPD-1T cellsImmune responseMurine colorectal cancer cellsBALB/c miceDual checkpoint inhibitionExpression of TIM3Subcutaneous flank injectionNumber of CD8PD-1 inhibitionImmune checkpoint blockadeDeficient mismatch repairColorectal cancer cellsHigh microsatellite instabilitySignificant clinical impactPotential escape mechanismsCombination immunotherapyImmunosuppressive checkpointsCheckpoint inhibitorsMonotherapy groupCheckpoint blockadeMost patients